Dextroamphetamine


Description

Dextroamphetamine is the dextrorotary enantiomer of amphetamine[A2505]. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[

Read more

Pharmacology

Indication

Dextroamphetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD)[... Read more

Pharmacodynamic

Dextroamphetamine is a noncatecholamine, sympathomimetic amine that acts as a CNS stimulant[Label].... Read more

Mechanismofaction

The exact mechanism of amphetamines as a class is not known. Dextroamphetamine acts by preventing re... Read more

Absorption

Bioavailability data of dextroamphetamine is not readily available, however there is no difference i... Read more

Proteinbinding

Information currently not available.

Volumeofdistribution

195L[ Read more

Clearance

17L/h[ Read more

Halflife

11.75 hours[Label]. In a study of post-stroke patients the half life was 16.0 hours in females and 1... Read more

Routeofelimination

A third of the drug is eliminated renally[A2505].

Toxicity

Dexrtoamphetamine has been shown to be teratogenic and embryotoxic in mice at 41 times the maximum h... Read more


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Cardiomyopathy US
Varying Reports
Elevated Blood Pressure US
Varying Reports
Restlessness US
Varying Reports
Overstimulation US
Varying Reports
Insomnia US
Varying Reports
Dizziness US
Varying Reports
Dyskinesia US
Varying Reports
Euphoria US
Varying Reports
Tachycardia US
Varying Reports
Palpitation US
Varying Reports
Changes in libido US
Varying Reports
Rhabdomyolysis US
Varying Reports
Urticaria US
Varying Reports
Impotence US
Varying Reports
Anorexia US
Varying Reports
Weight Loss US
Varying Reports
Constipation US
Varying Reports
Gastrointestinal disturbances US
Varying Reports
Unpleasant taste US
Varying Reports
Diarrhea US
Varying Reports
Tourette’s syndrome US
Varying Reports
Dryness of the mouth US
Varying Reports
Headache US
Varying Reports
Exacerbation of motor and phonic tics US
Varying Reports
Dysphoria US
Varying Reports
Tremor US
Varying Reports

Contraindications

  • Route:
    • Oral
  • Dose Form:
    • Tablet
    • Tablet, extended release
  • Hypersensitivity:
    • True
  • Sex Group: all
  • Regions: US
  • Regions: US
  • Patient Conditions:
      • Name: Advanced arteriosclerosis
      • Drugbank Id: DBCOND0107486
  • Regions: US
  • Patient Conditions:
      • Name: Symptomatic cardiovascular disease
      • Drugbank Id: DBCOND0107487
      • Modification Of:
        • Base:
          • Name: Cardiovascular Disease
          • Drugbank Id: DBCOND0028376
        • Severity:
          • Includes:
            • symptomatic
  • Regions: US
  • Patient Conditions:
      • Name: Moderate to Severe Hypertension
      • Drugbank Id: DBCOND0042937
  • Regions: US
  • Patient Conditions:
      • Name: Hyperthyroidism
      • Drugbank Id: DBCOND0009048
  • Regions: US
  • Patient Conditions:
      • Name: Glaucoma
      • Drugbank Id: DBCOND0010013
  • Regions: US
  • Patient Conditions:
      • Name: Agitated states
      • Drugbank Id: DBCOND0108374
  • Regions: US
  • Patient Conditions:
      • Name: History of drug abuse
      • Drugbank Id: DBCOND0107489
  • Regions: US
  • With Categories Coadmin:
      • Name: Monoamine Oxidase Inhibitors
      • Drugbank Id: DBCAT001004
      • Mesh Id: D008996

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Dextroamphetamine

The risk or severity of hypertension can be increased when Dextroamphetamine is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.
The therapeutic efficacy of 1-benzylimidazole can be decreased when used in combination with Dextroamphetamine.
The risk or severity of serotonin syndrome can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Dextroamphetamine.
The risk or severity of serotonin syndrome can be increased when Dextroamphetamine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 3-isobutyl-1-methyl-7H-xanthine.
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 3,5-diiodothyropropionic acid.
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 3,5-Diiodotyrosine.
The risk or severity of serotonin syndrome can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Dextroamphetamine.
The risk or severity of hypertension can be increased when 4-Methoxyamphetamine is combined with Dextroamphetamine.
The risk or severity of serotonin syndrome can be increased when Dextroamphetamine is combined with 5-methoxy-N,N-dimethyltryptamine.
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 6-O-benzylguanine.
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 7-Deazaguanine.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Dextroamphetamine.
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 7,9-Dimethylguanine.
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 8-azaguanine.
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 8-chlorotheophylline.
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 9-Deazaguanine.
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 9-Methylguanine.
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Abaloparatide.
The metabolism of Dextroamphetamine can be increased when combined with Abatacept.

References

  • 1 . de la Torre R, Farre M, Navarro M, Pacifici R, Zuccaro P, Pichini S: Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices. Clin Pharmacokinet. 2004;43(3):157-85. doi: 10.2165/00003088-200443030-00002. [PubMed: 14871155]
  • 2 . Saunders C, Galli A: Insights in how amphetamine ROCKs (Rho-associated containing kinase) membrane protein trafficking. Proc Natl Acad Sci U S A. 2015 Dec 22;112(51):15538-9. doi: 10.1073/pnas.1520960112. Epub 2015 Nov 25. [PubMed: 26607447]
  • 3 . Dolder PC, Strajhar P, Vizeli P, Hammann F, Odermatt A, Liechti ME: Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects. Front Pharmacol. 2017 Sep 7;8:617. doi: 10.3389/fphar.2017.00617. eCollection 2017. [PubMed: 28936175]
  • 4 . Calipari ES, Ferris MJ: Amphetamine mechanisms and actions at the dopamine terminal revisited. J Neurosci. 2013 May 22;33(21):8923-5. doi: 10.1523/JNEUROSCI.1033-13.2013. [PubMed: 23699503]
  • 5 . FDA Drug Approval Package for Dextroamphetamine [Link]

Recent Questions